Recent

% | $
Quotes you view appear here for quick access.

Assured Guaranty Ltd. Message Board

bocamp1 244 posts  |  Last Activity: 4 hours ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bocamp1 by bocamp1 Apr 26, 2015 5:55 PM Flag

    Makes the amgn/cytk heart drug partnership worth even more. Results 2nd half.

    SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR(R) (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug and device regimen.

  • RGN-352 deserves a shot. RGRX should be able to partner this drug. Heart indication is huge and big pharma has wasted 100's of miilions on failed attempts.

    SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR(R) (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug and device regimen.

  • bocamp1 by bocamp1 Apr 24, 2015 6:07 PM Flag

    Did a very exact 150,000 shares today. Can you imagine how high stock would be without all this naked shorting? This guy has shorted all the way up. He is keeping quite the "orderly" market.....
    Lots of round size ticks today, and most of the larger ones were no doubt the short; the 50k who hit the arca buyer at .465 was the short. And lots of stock done at .47 with the short capping buyers by offering 50k at .475. (Closed above that large tick; very positive)
    Its all getting very predictable. What must really make the short think twice is that this recent runnup is on really no news. And we know lots of news coming. Short at first played for what looked like a certain BK here. But recent deals take that way off the table, so stock rallies hard. Now, short is hoping for something, but only positives pending. Well, short has plenty of capital behind him, and he is going to need it.

  • Reply to

    Sno

    by bocamp1 Apr 24, 2015 4:09 PM
    bocamp1 bocamp1 Apr 24, 2015 4:31 PM Flag

    Sno, someday they will be in the Russell; maybe next year. But, they dont take this otc, pink or bb stocks and minimum buck stock price needed.
    No harm no foul. Have a good one

  • bocamp1 by bocamp1 Apr 24, 2015 4:09 PM Flag

    I guess you did a little more research on your Russell Rant......lol
    As i said, you should think before you write. Have a good weekend.
    Another good week on the whole for shareholders but shorts were hard at work to cap gains. More news next week should do it

  • After big volume day, we now do this. What a scam Ma is running. Any shareholder who isnt fed up with this guy and his incompetence is just brain dead. It amazes me that Ma can get paid so much, for doing so little.
    FUMA

  • Reply to

    Arca Action

    by bocamp1 Apr 24, 2015 11:26 AM
    bocamp1 bocamp1 Apr 24, 2015 11:31 AM Flag

    Twitter is saying consolidation breakout, with volume needed to confirm. Should get at least 400k today to confirm.

  • bocamp1 by bocamp1 Apr 24, 2015 11:26 AM Flag

    For the first time since i have followed stock, we have blocks done on arca. Typically, this venue is used for those that do not want to be identified. 50k at .465(most likely done a while ago but reported late;imho) and 35k at .49. Something cooking?

  • Reply to

    Trading

    by bocamp1 Apr 24, 2015 9:45 AM
    bocamp1 bocamp1 Apr 24, 2015 10:39 AM Flag

    Shorts really trying to defend that .48 price. Offer there was hit for 27,500 shares and size stayed the same. Just a matter of time..............................

  • bocamp1 by bocamp1 Apr 24, 2015 9:45 AM Flag

    Critical area here short term. If we can break .48, warrant price will be at risk for those short equity against them. News over the weekend?

  • bocamp1 by bocamp1 Apr 23, 2015 5:58 PM Flag

    Declared, same as before; NO cut. Analysts were looking for a cut, stock should rally into that payment.

  • Reply to

    Heart Area

    by bocamp1 Apr 23, 2015 1:54 PM
    bocamp1 bocamp1 Apr 23, 2015 3:31 PM Flag

    Mia, as i said, you are a fool. Yes, of course, TB4 is useless, just like our 300% returns so far this year. Good luck to you Mia, cause as the great Fred Sanford once said to his son. "Life is hard, but its even harder if your stupid."

  • Reply to

    Heart Area

    by bocamp1 Apr 23, 2015 1:54 PM
    bocamp1 bocamp1 Apr 23, 2015 3:18 PM Flag

    Are you serious ,FL? Stock rallies to fill gap to high of year, straight up 300+% for year, and you dont expect a pullback? Stock was headed into the mid .30's and has rallied right back on news on a patent. Lots of buyers on weakness here; a very good sign

  • Reply to

    Heart Area

    by bocamp1 Apr 23, 2015 1:54 PM
    bocamp1 bocamp1 Apr 23, 2015 3:07 PM Flag

    Hey Mia, it must burn your elitist butt that you sat back and bashed company while it has rallied over 300% this year. What a fool you are.
    Patent easily extended. And you know the answers to the last 2 questions. But, real answer is that it doesnt matter. Of course trial would take years and cost much. But, cost of trial would be assumed by partner(as amgn has done with Omecamtiv mecarbil and cytk) and rgrx would get milestones along the way. The real benefit to a company with such a low stock price would be a huge spike in price immediately on signing of any partership since no value assigned to RGN 352 right now. As an astute investor, you know all this to be true.
    Good luck to you, mia

  • bocamp1 by bocamp1 Apr 23, 2015 1:54 PM Flag

    The environment for partnering a drug for CHF has completely changed in the last year. Its no coincidence that heart patent announced at this time. RGRX hasnt been able to partner this indication in the past, but huge sums being spent by Big pharma right now for heart. Bio's are all about whats is hot today. Look at the bmy deal. If you listened to amgn cc, you heard them talk up the 200+ million they have spent on the partnership with cytk for heart drug. CLDN about to come with P2 trial results on CHF drug(300 mil market cap with no revs).
    And once one pharma starts spending money, more and more must get into the area to stay competitive; just look at the CarT area for cancer. Biilions being spent by all pharmas.
    RGRX right now gets NO value for RGN-352. It can only add to market cap once this under followed bio starts getting coverage. A couple million dollar partnership with some royalties is nothing for big pharma and would let them show their shareholders they have the heart area covered. Its can happen anytime. That is why selloffs are so shallow here; much news pending.

  • Reply to

    Huge Call volume

    by bocamp1 Apr 23, 2015 9:44 AM
    bocamp1 bocamp1 Apr 23, 2015 12:56 PM Flag

    Looks like you dont know what you are talking about. You can check the OI tomorrow to see just how wrong you are. Another message board expert....................

  • Reply to

    Huge Call volume

    by bocamp1 Apr 23, 2015 9:44 AM
    bocamp1 bocamp1 Apr 23, 2015 9:48 AM Flag

    VDSI in play. 100 contract buyers all over the place here.

  • In the june 35 calls this morning. Over 3000 bought at .55. Thats a buyout play. Follow the money

  • Reply to

    Increase in volume

    by gryzter Apr 21, 2015 11:05 AM
    bocamp1 bocamp1 Apr 23, 2015 9:39 AM Flag

    Hard to figure out what is going on here. Big volume in the morning here and all selling so far. What is Ma up to.? Company must do a buyback at these prices if cash balances are really as large as stated.
    Is a big acquisition about to be done? That would explain selling, as Ma has no credibility in that regard.
    Vaso is the gift that just keeps giving shareholders.
    Need a huge volume day to get that bottom. Could this be happening today?

  • Bristol-Myers Squibb said Monday that it will work with uniQure to develop gene therapies for cardiovascular diseases, starting with a potential treatment for congestive heart failure that is intended to restore the heart's ability to synthesize a protein called S100A1. The deal could be worth more than $2.2 billion. Bristol-Myers Squibb will also take a minority stake in the company.
    Drug may get approved in 2018

    What is RGN-352 worth? This is just a white hot area. RGRX has failed to partner in the past, for pennies on the dollar big pharma could take a shot.

AGO
26.16+0.27(+1.04%)May 4 4:04 PMEDT